Evidence map›Paper›PMID 31328183›Full record

ArticleJournal of cancer treatment & diagnosis2018

Constitutive Aryl Hydrocarbon Receptor Signaling in Prostate Cancer Progression.

Maryam Ghotbaddini, Vivian Moultrie, Joann B Powell

Open access · diamondAbstract read
In one paragraph

Article in Journal of cancer treatment & diagnosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maryam GhotbaddiniClark Atlanta University- Center for Cancer Research and Therapeutic Development 223 James P Brawley Drive Atlanta, Georgia, USA.
Vivian MoultrieClark Atlanta University- Center for Cancer Research and Therapeutic Development 223 James P Brawley Drive Atlanta, Georgia, USA.
Joann B PowellClark Atlanta University- Center for Cancer Research and Therapeutic Development 223 James P Brawley Drive Atlanta, Georgia, USA.
Atlanta University Center · US

Funding

The Hampton University regional Transdisciplinary Collaborative CenterU54MD008621 · NIMHD · HAMPTON UNIVERSITY · PI SAMUEL, RAYMOND E · 2013 to 2017
$13.5M
Technologies/Resources for Core LaboratoriesG12MD007590 · NIMHD · CLARK ATLANTA UNIVERSITY · PI KHAN, SHAFIQ A · 2012 to 2018
$7.6M
NIMHD NIH HHS G12 MD007590NIMHD NIH HHS U54 MD008621
6 · The paper itself

Abstract

Research on the aryl hydrocarbon receptor (AhR) has largely focused on its activation by various environmental toxins. Consequently, only limited inferences have been made regarding its constitutive activity in the absence of an exogenous ligands. Evidence has shown that AhR is constitutively active in advanced prostate cancer cell lines which model castration resistant prostate cancer (CRPC). CRPC cells can thrive in an androgen depleted environment. However, AR signaling still plays a major role. Although several mechanisms have been suggested for the sustained AR signaling, much is still unknown. Recent studies suggest that crosstalk between constitutive AhR and Src kinase may sustained AR signaling in CRPC. AhR forms a protein complex with Src and plays a role in regulating Src activity. Several groups have reported that tyrosine phosphorylation of AR protein by Src leads to AR activation, thereby promoting the development of CRPC. This review evaluates reports that implicate constitutive AhR as a key regulator of AR signaling in CRPC by utilizing Src as a signaling intermediate.

Indexed as

ARAryl Hydrocarbon ReceptorCastration Resistant Prostate CancerCrosstalkPhosphorylationSrc Kinase

Identifiers

PMID31328183
PMCPMC6641558
OpenAlexW2903424051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.